OGT and cancer: Increased protein O-GlcNAcylation and changes in OGT and/or OGA expression have now been described in different cancer types including breast (30–, 32), lung (33), colon (33), liver (34), bladder (35), endometrial (36) prostate (37), and chronic lymphocytic leukemia (CCL) cells (38).